GALECTIN THERAPEUTICS INC.

(GALT)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
1.280 USD   -3.03%
05/17HC Wainwright Adjusts Price Target on Galectin Therapeutics to $11 From $14, Reiterates Buy Rating
MT
05/16Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
AQ
05/16GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galectin Therapeutics Inc. announced that it has received $20 million in funding

12/21/2021 EDT

On December 21, 2021, Galectin Therapeutics Inc. closed the transaction. The company received $10,000,000 in its second and final tranche. The company has received $20,000,000 in the transaction so far.


© S&P Capital IQ 2021
All news about GALECTIN THERAPEUTICS INC.
05/17HC Wainwright Adjusts Price Target on Galectin Therapeutics to $11 From $14, Reiterates..
MT
05/16Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 an..
AQ
05/16GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition ..
AQ
05/16Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/16NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
04/14Galectin Therapeutics Says Study of Liver Disease Drug Candidate to Proceed Without Cha..
MT
04/14Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitor..
AQ
04/14Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitor..
CI
04/14GALECTIN THERAPEUTICS : Reports the Positive Outcome of the First Data and Safety Monitori..
PU
04/14GALECTIN THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on GALECTIN THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -46,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,71x
Yield 2022 -
Capitalization 76,0 M 76,0 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 9
Free-Float 59,9%
Chart GALECTIN THERAPEUTICS INC.
Duration : Period :
Galectin Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALECTIN THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,28 $
Average target price 11,00 $
Spread / Average Target 759%
EPS Revisions
Managers and Directors
Joel Lewis President, Chief Executive Officer & Director
Jack W. Callicutt Chief Financial Officer & Secretary
Richard E. Uihlein Chairman
Pol F. Boudes Chief Medical Officer
Ezra R. lowe Executive Director-Clinical
Sector and Competitors
1st jan.Capi. (M$)
GALECTIN THERAPEUTICS INC.-38.16%76
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567